TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial.
Thorax
; 78(8): 816-824, 2023 08.
Article
in En
| MEDLINE
| ID: mdl-37024277
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Respiratory Distress Syndrome
/
COVID-19
Type of study:
Clinical_trials
/
Etiology_studies
/
Guideline
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Thorax
Year:
2023
Document type:
Article
Affiliation country:
Estados Unidos